April 27, 2009 (FinancialWire) — Vasogen Inc. (NASDAQ: VSGN) (TSX: VAS) (Current Market Cap: US$4.05 Mil.) has named Eldon R. Smith as chairman. He will succeed Terrance H. Greg, who resigned from Vasogen’s board due to the requirements of his role as president and CEO of DexCom, Inc.

Smith, a Vasogen board member since 1998, is professor emeritus at the University of Calgary, Alberta, where he served as the dean of the faculty of medicine subsequent to being head of the university’s department of medicine and its division of cardiology.

Canada-based Vasogen is a biotechnology company that has been engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neuro-inflammatory disorders.

Vasogen is not currently advancing the development of our products and is focused on exploring strategic options that may include a sale of the company to a third party, merger, an acquisition by Vasogen, or other strategic alternative.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.